Drs Whitman and Patel discuss the evolving treatment paradigm for patients with CSCC, emphasizing the role of neoadjuvant and adjuvant immunotherapies.
Eric Whitman, MD
Advertisement
Eric Whitman, MD, medical director, oncology service line, Atlantic Health System
Articles by Eric Whitman, MD
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses eliminating financial toxicity in oncology.
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses improving precision medicine in oncology.
Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses the partnership between Atlantic Health System, Translational Genomics Research Institute (TGen), and Origin Commercial Ventures.
Eric Whitman, MD, surgeon, Atlantic Health System, discusses the role of pembrolizumab (Keytruda) in the treatment of patients with melanoma.
Advertisement
Latest Updated Articles
Dr. Whitman on the Role of Pembrolizumab in MelanomaMarch 14th 2018
Dr. Whitman on Improving Precision Medicine in OncologyOctober 9th 2018
Dr. Whitman on Eliminating Financial Toxicity in OncologyOctober 16th 2018
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus Lenalidomide/Rituximab Win EU Approval for R/R Follicular Lymphoma
2
FDA Issues CRL to Orviglance for Liver Metastasis Imaging in Patients With Severe Kidney Impairment
3
Adagrasib Plus Cetuximab Misses OS, PFS End Points in Pretreated KRAS G12C–Mutated CRC
4
Phase 1 Data Highlight Potential Utility for In Vivo CAR T-Cell Therapy in R/R Myeloma
5